This inventor holds 3 USPTO granted patents and 8 published patent applications and 1 EPO patent. Top assignees: Secama Pharmaceuticals Gmbh & Co Kg, Secarna Pharmaceuticals Gmbh & Co Kg, Secarna Pharmaceuticals Gmbh & Co. Kg. Active years: 2020-2026.
Company Filing History:
1 out of 1 
1 out of 3 
1 out of 1 Years Active: 2020-2026
Title: Sven Michel: Innovator in Antisense Oligonucleotide Technology
Introduction
Sven Michel is a notable inventor based in Bernried, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antisense oligonucleotides. With a total of 3 patents to his name, Michel's work focuses on innovative solutions for gene expression inhibition.
Latest Patents
One of Sven Michel's latest patents is titled "Modified antisense oligonucleotide for inhibition of FoxP3 expression." This invention involves oligonucleotides that inhibit the expression of Chop, specifically targeting the C/EBP-homologous protein (Chop). The oligonucleotide consists of 10 to 25 nucleotides, with at least one modified nucleotide. It is designed to hybridize with nucleic acid sequences of Chop in humans, mice, and rats, achieving at least 50% inhibition of Chop expression. Additionally, the invention includes a pharmaceutical composition comprising such oligonucleotides.
Career Highlights
Sven Michel has worked with several prominent companies in the pharmaceutical sector. Notably, he has been associated with Secama Pharmaceuticals GmbH & Co. KG and Secarna Pharmaceuticals GmbH & Co. KG. His experience in these organizations has allowed him to further his research and development efforts in the field of biotechnology.
Collaborations
Throughout his career, Sven Michel has collaborated with various professionals in the industry. Some of his notable coworkers include Frank Jaschinski and Richard Klar. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Sven Michel is a distinguished inventor whose work in antisense oligonucleotide technology has the potential to impact therapeutic approaches significantly. His innovative patents and collaborations reflect his commitment to advancing biotechnology.